clinical trial · NCT07354516
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Qlaris Bio, Inc.·phase3·recruiting·n = 60
OAG - Open-Angle GlaucomaOHT - Ocular HypertensionQLS-111-FDCLatanoprost (0.005%)
brief summary
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
started
Mar 18, 2026
primary completion
Jul 1, 2026
completion
Jul 15, 2026
last updated
Apr 3, 2026
detailed description
14-day prospective, double-masked, active-controlled, randomized multicenter study comparing QLS-111-FDC and PF latanoprost. Study is comprised of 5 visits.
official title
A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol